Healthcare / Medical DevicesShanghai
$13.60
+0.13 (+0.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $319.1M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.3B
P/E
16.8x
↓EV/EBITDA
7.3x
↓ROE
6.9%
↑Gross Margin
25.1%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
+31.5%
FCF margin
3.3%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.74B · net income $526.3M · FCF $319.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.74B | $9.74B | $10.02B | $10.01B | $9.28B |
| Net Income | $526.3M | $526.3M | $691.6M | $654.0M | $500.1M |
| EBITDA | $866.0M | $866.0M | $1.05B | $998.8M | $830.4M |
| EPS | 0.87 | 0.87 | 1.14 | 1.09 | 0.95 |
| Gross Margin | 25.1% | 25.1% | 26.1% | 26.5% | 26.4% |
| Operating Margin | 7.2% | 7.2% | 9.0% | 8.1% | 7.5% |
| Net Margin | 5.4% | 5.4% | 6.9% | 6.5% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.15 | 0.15 | 0.22 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $319.1M | $319.1M | $29.8M | $494.3M | $140.5M |
| Returns | |||||
| ROE | 6.9% | 6.9% | 9.1% | 8.9% | 9.3% |
| Valuation | |||||
| P/E | 16.79 | 16.79 | 14.18 | 22.67 | 24.10 |
| EV/EBITDA | 7.30 | 7.30 | 7.61 | 12.73 | 13.91 |
| P/B | 1.08 | 1.08 | 1.29 | 2.03 | 2.24 |
| Growth & Yield | |||||
| Revenue Growth | -2.8% | -2.8% | 0.1% | 7.9% | — |
| EPS Growth | -23.7% | -23.7% | 4.6% | 15.2% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.5%
EPS terminal req.
$1.21
Spread vs growth
-35.2%
5Y implied EPS CAGR
10.9%
EPS terminal req.
$1.46
Spread vs growth
-34.6%
10Y implied EPS CAGR
10.5%
EPS terminal req.
$2.35
Spread vs growth
-34.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.7%
Start / end P/E
13.5x → 15.6x
EPS bridge
1.14 → 0.87
Residual
-3.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.